Neuroimmunology Drug Development Summit 2023

Ulysses Neuroscience Ltd. recently attended the Neuroimmunology Drug Development Summit (26-27 April) in Boston, where our Founder/President & CEO Massimiliano Bianchi gave a talk entitled “An Update on Neuroinflammation Research Capabilities of Ulysses Neuroscience Ltd“.


During the summit we also presented two posters, with our CSO Dr. John Kealy presenting “Interferon-alpha administration as a model of neuroinflammation to test antidepressant and anti-inflammatory drugs” and our Preclinical Biomarker Lead Dr. Johana Tello presenting “A preformed fibril (PFF) rat model of synucleinopathy as a tool to investigate neuroinflammation and synaptic dysfunction in Parkinson’s Disease“.

Thank you to everyone who met with us during our time in Boston and thanks to Hanson Wade Group for organising the 5th Neuroimmunology Drug Development Summit – we are proud to partner with you in bringing science forward in the field of neuroimmunology and glad to be part of some innovative research happening in the field. Exciting times ahead for Ulysses Neuroscience!